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A B S T R A C T
Clostridium diﬃcile infection (CDI) is the leading cause of infectious healthcare-associated diarrhoea. Re-
current CDI increases disease morbidity and mortality, posing a high burden to patients and a growing
economic burden to the healthcare system. Thus, there exists a signiﬁcant unmet and increasing medical
need for new therapies for CDI. This review aims to provide a concise summary of CDI in general and a
speciﬁc update on ridinilazole (formerly SMT19969), a novel antibacterial currently under develop-
ment for the treatment of CDI. Owing to its highly targeted spectrum of activity and ability to spare the
normal gut microbiota, ridinilazole provides signiﬁcant advantages over metronidazole and vancomy-
cin, the mainstay antibiotics for CDI. Ridinilazole is bactericidal against C. diﬃcile and exhibits a prolonged
post-antibiotic effect. Furthermore, treatment with ridinilazole results in decreased toxin production. A
phase 1 trial demonstrated that oral ridinilazole is well tolerated and speciﬁcally targets clostridia whilst
sparing other faecal bacteria. Phase 2 and 3 trials will hopefully further our understanding of the clin-
ical utility of ridinilazole for the treatment of CDI.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
1.1. Overview and epidemiology
Clostridium diﬃcile is an anaerobic, spore-forming, Gram-
positive bacillus ﬁrst identiﬁed in 1978 as the causative agent of
pseudomembranous colitis in humans [1]. Symptoms of C. diﬃcile
infection (CDI) range from mild to moderate diarrhoea, often with
cramping abdominal pain, to fulminant disease, which can mani-
fest as severe diarrhoea, colitis, toxic megacolon, bowel perforation
and sepsis [2].
Outbreaks of severe CDI in the USA and Canada in the early 2000s
were attributed to the rapid emergence of a ﬂuoroquinolone-
resistant strain of C. diﬃcile characterised as REA group BI, pulsed-
ﬁeld gel electrophoresis (PFGE) type NAP1, and PCR ribotype 027
(BI/NAP1/027) [3–5]. The rapid transcontinental spread of two dis-
tinct lineages of the BI/NAP1/027 epidemic strain has driven the
increased frequency and severity of global CDIs [6]. CDI is now the
leading cause of infective healthcare-associated diarrhoea [7]. A US
surveillance study funded by the US Centers for Disease Control and
Prevention (CDC) estimated the national incidence of CDI in 2011
at almost half a million cases with ca. 29,000 deaths within 30 days
of initial diagnosis [8]. Epidemic C. diﬃcile 027 remains the most
common ribotype in the USA and accounts for approximately one-
third of cases [9,10]. The overall prevalence of ribotype 027 in Europe
has increased more than three-fold from 2008 to 2013, notably in
Eastern European countries and in Germany [11]. Ribotype 027 and
other hypervirulent strains, including ribotypes 078, 126 and 244,
are associated with fulminant disease, increased risk of life-
threatening complications and increased rates of mortality [12–15].
CDI has traditionally been thought of as a nosocomial infec-
tion, but the increasing frequency of community-associated CDI has
underscored the growing threat of C. diﬃcile transmission outside
of the hospital setting [16–18]. A 2012 CDC report showed that 94%
of CDI cases were associatedwith contact with the healthcare system,
but in 75% of cases disease onset occurred in non-hospitalised pa-
tients and 52% of CDI cases were already present on admission [19].
Interestingly, and as yet unexplained, approximately one-third of
community-associated CDIs do not have a history of recently pre-
scribed antibiotics; other precipitating factors that could be relevant
are foodstuffs, including antimicrobial substances therein, and other
drugs that may alter the gut microbiome [20–23].
CDI disproportionately affects the elderly, with the incidence of
CDI highest in those aged ≥65 years [8], and elderly individuals with
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CDI experience poorer treatment outcomes [24]. Antibiotic use
remains the primary risk factor for CDI, and the majority of anti-
biotic classes in routine clinical use are associated to a greater or
lesser degree with CDI [25,26].
1.2. Virulence factors
C. diﬃcile secretes two major virulence factors, enterotoxin TcdA
(toxin A) and cytotoxin TcdB (toxin B), which are the primary causes
of inﬂammation and damage to the colonic mucosa, resulting in
disease symptoms [27]. The cytotoxic effects of toxins A and B are
mediated by their ability to glucosylate and inactivate epithelial cell
GTPases such as Rac, Rho and Cdc42, which leads to alterations in
cellular signalling that affect the actin cytoskeleton, disrupt barrier
function and induce apoptosis. Some toxin B variants target Ras and
Rap GTPases in place of Rac. Toxins A and B also contribute to tissue
damage through their induction of pro-inﬂammatory cytokines such
as interleukin 1-beta (IL-1β) [27]. Toxin B from ribotype 027 is as-
sociated with increased cytotoxicity, which may contribute to
enhanced virulence [28]. Hypervirulent strains produce a third toxin
known as C. diﬃcile binary toxin (CDT). The role of this toxin in vir-
ulence has yet to be determined, although its presencemay be linked
to more severe disease [27,29,30]. Furthermore, there have been
recent cases reported of CDI due to strains producing only CDT
[31,32].
Hypervirulent strains are also potentially associated with in-
creased spore production [33,34]. C. diﬃcile spores play a major role
in the pathogenesis of CDI [35]. Spores shed in the faeces of in-
fected or colonised individuals are resistant to heat, acid and alcohol-
based cleaners; thus, dormant spores can persist for months on
environmental surfaces in healthcare settings and the community
[36,37]. C. diﬃcile spores act as the vector for infection, with trans-
mission occurring through spore ingestion via the faeco–oral route
[38].
1.3. Treatment options and disease recurrence
Treatment of CDI has largely been limited to the antibiotics met-
ronidazole and vancomycin. Most current guidelines state that oral
metronidazole is recommended for non-severe disease, whereas oral
vancomycin is the preferred therapy for severe disease [39,40].
Notably, it has recently been shown that vancomycin results in su-
perior clinical cure rates compared with metronidazole in patients
both with non-severe and severe CDI [41,42]. This now raises ques-
tions about the place of metronidazole in the treatment options
for CDI.
Fidaxomicin (Diﬁclir®, Astellas, Europe; Diﬁcid®, Merck, USA) was
approved in 2011 for the treatment of CDI. In phase 3 studies,
ﬁdaxomicin has been shown to be non-inferior to vancomycin on
clinical response at the end of treatment (EOT) and superior to van-
comycin on sustained clinical response to 28 days post-EOT. However,
ﬁdaxomicin was not shown to be superior to vancomycin on sus-
tained clinical response in patients infectedwith BI/NAP1/027 strains
[43,44].
Disease recurrence remains a central unmet medical need in the
management of CDI. Following initial therapy with metronidazole
or vancomycin, recurrence of CDI occurs in up to 30% of patients,
and each episode of disease is associated with an increased risk of
additional recurrent episodes. In a study of 163 patients with at least
one recurrent CDI episode, the risk of subsequent episodes was 45%
[45]. Following a third episode of CDI, recurrence rates may be >65%
[46,47]. Disease recurrence poses a signiﬁcant burden to patients,
diminishing quality of life and increasing morbidity and mortality.
Treatment of recurrent CDI is challenging and there is no uni-
formly effective therapeutic approach. For the ﬁrst recurrent episode,
the most recent treatment guidance, published by the European
Society of Clinical Microbiology and Infectious Diseases (ESCMID),
recommends continued use of the agent employed to treat the initial
infection or the use of either vancomycin or ﬁdaxomicin [39]. In
treating a ﬁrst recurrence of CDI, ﬁdaxomicin has been shown to
be associated with reduced rates of subsequent recurrences com-
pared with vancomycin [44]. For multiple recurrences, either
vancomycin with a tapered and/or pulsed dosing regimen or
ﬁdaxomicin is preferred [39].
Therapeutic options become less clear in cases of complicated
CDI (fulminant disease that is refractory to antibiotic therapy and
may progress to toxic megacolon, bowel perforation or systemic tox-
icity); total abdominal colectomywith ileostomymay be necessitated
[39]. Diverting loop ileostomy combined with intracolonic and in-
travenous antibiotic therapy is a less invasive alternative to total
colectomy and is currently in clinical trials for the treatment of com-
plicated CDI [39,48].
Faecal microbiota transplantation (FMT) has emerged as an al-
ternative therapy for multiple recurrent CDI. In FMT, healthy donor
faeces are introduced into the gut of patients with recurrent CDI.
FMT is thought to work by restoring the diversity of the intestinal
microbiota, which is essential for colonisation resistance [49,50].
Systematic reviews of FMT have demonstrated the success of this
therapy, with cure rates of ca. 90% [51,52]. The ﬁrst randomised
controlled trial (RCT) of FMT, which was a small, open-label study,
demonstrated the eﬃcacy of oral vancomycin combined with
nasoduodenal infusion of donor faeces over vancomycin therapy
alone (81% vs. 23–31% clinical cure, respectively) for the treatment
of multiple recurrent CDI [53]. In addition, FMT has shown eﬃca-
cy in cases of fulminant CDI [54]. FMT is a promising alternative
therapy for multiple recurrent CDI and it is now recommended, in
combination with oral vancomycin, for the treatment of multiple
recurrent CDI [39]; however, the long-term safety of the proce-
dure remains unclear, especially as more is learnt regarding the far-
reaching effects of the human gut microbiome.
In addition to FMT, the oral microbiome therapeutics SER-109
and RBX2660 appear to be promising bacteriotherapies for CDI
[55,56].
2. Ridinilazole (formerly SMT19969)
Ridinilazole [2,2′-bis(4-pyridyl)3H,3′H 5,5′-bibenzimidazole] is
a novel antibacterial that does not appear to act through the clas-
sical pathways associated with antibiotics, such as inhibition of cell
wall, protein, lipid, RNA or DNA synthesis. In ﬂuorescent-labelling
studies, treatment of C. diﬃcilewith antibiotic concentrations below
the minimum inhibitory concentration (sub-MICs) of ridinilazole
resulted in a ﬁlamentous phenotype with replicated nucleoids along
the length of the cell and no observed septum formation, indicat-
ing that ridinilazolemay impair cell division [57]. Ridinilazole is being
developed by Summit Therapeutics plc (Abingdon, UK).
2.1. In vitro eﬃcacy of ridinilazole
2.1.1. Minimum inhibitory concentration assays
In susceptibility testing of 82 clinical isolates of C. diﬃcile (in-
cluding ribotype 027), ridinilazole displayed potent growth inhibition
and had lower MICs [MIC range, 0.06–0.25 μg/mL; MIC for 90% of
the organisms (MIC90), 0.125 μg/mL] thanmetronidazole (MIC range,
0.125–8 μg/mL; MIC90, 8 μg/mL) or vancomycin (MIC range, 0.5–
4 μg/mL; MIC90, 2 μg/mL) [58,59]. Similarly, ridinilazole was found
to be more potent than metronidazole or vancomycin at inhibit-
ing the growth of 50 ribotype-deﬁned C. diﬃcile strains [60].
Ridinilazole-induced growth inhibition was also assessed in a
recent study of 107 C. diﬃcile clinical isolates covering a range
of deﬁned resistance phenotypes (e.g. resistance to antibiotics
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commonly associated with CDI) [61]. In this study, all isolates were
susceptible to ridinilazole, and cross-resistance was not observed.
The activity of ridinilazole against speciﬁc C. diﬃcile ribotypes
(including ribotypes 001, 002, 005, 014, 027, 054 and 106) was
similar, with an MIC range of 0.06–0.5 μg/mL and an MIC90 of
0.125 μg/mL (Table 1). These data demonstrate that there are no
major differences between C. diﬃcile ribotypes in terms of suscep-
tibility to ridinilazole. In addition, ridinilazole wasmore active against
11 ribotype 027 strains than either metronidazole or vancomycin
(Table 1).
Antibiotics for CDI (both marketed and in development) typi-
cally achieve gastrointestinal concentrations that are signiﬁcantly
in excess of the agent’s MIC. Metronidazole is an exception, as it is
highly absorbed following oral administration resulting in low in-
traluminal drug concentrations [62]. Isolates showing reduced
susceptibility to metronidazole that remain susceptible to other
agents, including ridinilazole, have been reported [63], and whilst
no link between clinical outcome, intraluminal concentration and
the MIC of metronidazole has been established, elevated MICs may
be a future consideration for metronidazole.
A comparative study of 174 Gram-positive and 136 Gram-
negative intestinal anaerobes showed both ridinilazole and
ﬁdaxomicin to be inactive (MIC90 > 512 μg/mL) against Bacteroides
spp. (including Bacteroides fragilis, Bacteroides ovatus, Bacteroides
thetaiotaomicron and Bacteroides vulgatus) [60]. Whereas ridinilazole
was relatively inactive against these species, metronidazole and van-
comycin MICs were generally in the ranges of 0.5–2 μg/mL and
8–256 μg/mL, respectively [60].
In general, ridinilazole and ﬁdaxomicin display limited activity
against Gram-negative anaerobes, which suggests that these drugs
could potentially spare the normal intestinal microbiota. Whereas
ﬁdaxomicin showed activity against a number of Gram-positive an-
aerobes, such as Biﬁdobacterium spp. and Eggerthella spp., ridinilazole
showed limited activity against these species with MIC90 values of
>512 μg/mL [60]. Ridinilazole also had limited activity against Gram-
positive aerobes, including Staphylococcus aureus, Enterococcus faecalis,
Streptococcus spp. and Enterococcus faecium [60].
The activity of ridinilazole against other Clostridium spp. was
species-dependent, with MIC90 values of >512 μg/mL for Clos-
tridium perfringens and Clostridium ramosum and 1 μg/mL for
Clostridium innocuum [60]. Similarly, in a study of 162 strains of 35
less frequently recovered intestinal Clostridium spp. in clusters I–XIX,
ridinilazole MICs ranged from 0.06 μg/mL to >512 μg/mL, and re-
sistance to ridinilazole was neither cluster- nor species-dependent
[64].
2.1.2. Bactericidal activity of ridinilazole
Ridinilazole displayed bactericidal activity against C. diﬃcile
ribotype 027, with all concentrations of ridinilazole resulting in a
>3.2 log10 reduction in CFU/mL at 24 h [58]. At most concentra-
tions tested, vancomycin was bacteriostatic against ribotype 027,
although a 3.1 log10 reduction in CFU/mL was observed at 2× MIC
at 24 h. Fidaxomicin was bacteriostatic against ribotype 027 at 1–10×
MIC and was bactericidal at only 20× MIC (ca. 5- to 50-fold lower
than the relative concentrations of drug in the gut) at 24 h. Whereas
vancomycin was generally bacteriostatic against C. diﬃcile ribotypes
012 and 078, both ridinilazole and ﬁdaxomicin were bactericidal
against these strains [58].
2.1.3. Post-antibiotic effect (PAE) of ridinilazole
Ridinilazole exhibited a prolonged PAE (4–20 h) against C. diﬃcile
ribotypes 012, 027 and 078 at high concentrations (10× MIC); there
was no growth recovery of C. diﬃcile strains following 1 h of
treatment at 20× MIC [58]. Vancomycin displayed a minimal PAE
(0–2 h) at all concentrations tested, whereas ﬁdaxomicin had a pro-
longed PAE (8–20 h) at ≥2× MIC [58], as previously reported.
2.1.4. Effect of ridinilazole on C. diﬃcile toxin production
Treatment of C. diﬃcile ribotype 027 (R20291) with either supra-
(4× and 40×) or sub- (0.5×) MICs of ridinilazole resulted in statistically
signiﬁcant reductions both in toxin A and toxin B concentrations
[57]. At 0.5× MIC of ridinilazole, toxin B was not detected and toxin
A was decreased by 80–90%. Toxin A and toxin B decreased by 80–
90% after 24 h of exposure to ridinilazole at supra-MIC. In addition,
treatment of Caco-2 cells with ridinilazole-treated culture super-
natants resulted in a marked 74% reduction in IL-8 release compared
with treatment with drug-free supernatants. Both vancomycin and
metronidazole controls showed similar levels of toxin production
and IL-8 release compared with drug-free controls [57].
2.1.5. Human gut model of C. diﬃcile infection
The narrow spectrum of activity of ridinilazole observed in MIC
assays was further supported by an in vitro human gut model of
clindamycin-induced CDI. In this clinically predictive model, faecal
emulsions are used to establish a steady-state gut microbiota in
Table 1
In vitro minimum inhibitory concentrations (MICs) of ridinilazole, ﬁdaxomicin,
vancomycin and metronidazole for distinct ribotypes of Clostridium diﬃcile.
Ribotype/Drug MIC (μg/mL) Reference
Range MIC50 MIC90
Ribotype 001 (n = 10)
Ridinilazole 0.06–0.125 0.125 0.125 [58]
Fidaxomicin 0.008–0.06 0.03 0.06
Vancomycin 0.5–4 1 4
Metronidazole 0.125–1 1 1
Ribotype 002 (n = 8)
Ridinilazole 0.125–0.25 0.25 NR [60]
Fidaxomicin 0.06–0.25 0.25 NR
Vancomycin 1–2 1 NR
Metronidazole 0.25–0.5 0.5 NR
Ribotype 005 (n = 3)
Ridinilazole 0.25 0.25 NR [60]
Fidaxomicin 0.06–0.25 0.25 NR
Vancomycin 2 2 NR
Metronidazole 0.5 0.5 NR
Ribotype 014 (n = 8)
Ridinilazole 0.125–0.25 0.125 NR [60]
Fidaxomicin 0.06–0.5 0.25 NR
Vancomycin 1–2 1 NR
Metronidazole 0.25–0.5 0.5 NR
Ribotype 027 (n = 11 [58];
n = 11 [60])
Ridinilazole 0.25–0.5 0.25 0.25 [60]
0.125–0.25 0.125 0.125 [58]
Fidaxomicin 0.5–1 0.5 0.5 [60]
0.03–0.06 0.06 0.06 [58]
Vancomycin 1–8 2 4 [60]
0.5–4 1 2 [58]
Metronidazole 2–8 2 8 [60]
1–2 2 2 [58]
Ribotype 054 (n = 4)
Ridinilazole 0.125–0.25 0.25 NR [60]
Fidaxomicin 0.125 0.125 NR
Vancomycin 1–2 1 NR
Metronidazole 0.5 0.5 NR
Ribotype 106 (n = 10 [58];
n = 3 [60])
Ridinilazole 0.25 0.25 NR [60]
0.125–0.25 0.125 0.125 [58]
Fidaxomicin 0.5 0.5 NR [60]
0.03–0.125 0.06 0.125 [58]
Vancomycin 1 1 NR [60]
0.5–4 1 2 [58]
Metronidazole 0.5 0.5 NR [60]
1–2 2 2 [58]
MIC50/90, MIC for 50% and 90% of the organisms, respectively; NR, not reported.
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pH-maintained fermentation vessels, which are subsequently in-
oculated with C. diﬃcile spores and then clindamycin to establish
CDI (as manifested by cytotoxin production) before treatment with
the test antimicrobial agent. This model has been used successfully
to assess the ability of antibiotics to induce CDI as well as to examine
the eﬃcacy of antimicrobial agents for CDI treatment [65–68].
Introduction of ridinilazole into the human gut model spared the
normal anaerobic microbiota whilst speciﬁcally inhibiting the vi-
ability of Clostridium spp. (2 log10 reduction in CFU/mL) [59].
Ridinilazole caused a rapid decline in C. diﬃcile cytotoxin titres, and
toxin remained undetectable in the ﬁnal days following cessation
of ridinilazole treatment. In this study, there was no evidence for
recurrent CDI in the gut model following ridinilazole treatment [59].
Taken together, these in vitro data demonstrate the narrow spec-
trum of activity of ridinilazole, which speciﬁcally targets C. diﬃcile
isolates whilst sparing other intestinal anaerobes and faecal aerobes.
2.2. In vivo eﬃcacy of ridinilazole
2.2.1. Preclinical animal models
The hamster model of clindamycin-induced CDI is the stan-
dard in vivomodel for CDI. Animals develop large bowel colonisation,
C. diﬃcile spore formation and, ultimately, fatal toxin-mediated gas-
trointestinal inﬂammation. The model includes an acute infection
and treatment phase followed, in some cases, by a period to monitor
for recurrent disease [69]. Compared with vancomycin, both
ridinilazole and ﬁdaxomicin displayed greater eﬃcacies in this model
against C. diﬃcile ribotype 027 strain [70]. A twice-daily dose of either
ridinilazole or ﬁdaxomicin conferred protection from CDI with 90–
100% survival of hamsters at Day 28, whereas twice-daily vancomycin
resulted in only 10% survival (see Fig. 1) [70]. Plasma levels of
ridinilazole were below the limit of detection, demonstrating the
low systemic absorption of ridinilazole from the gut [70].
Ridinilazole-treated hamsters were culture-negative for C. diﬃcile
spores for a longer period than ﬁdaxomicin-treated hamsters, with
higher doses of either of these agents inhibiting spore recovery from
faecal samples beginning at Day 7 and continuing through the 28-
day post-treatment follow-up period [70].
In a hamster model of CDI with a once-daily dosing regimen,
ridinilazole displayed greater eﬃcacy than vancomycin both against
non-epidemic and epidemic strains of C. diﬃcile [71]. Similar to the
twice-daily dosing study, plasma levels of ridinilazole were below
the level of detection, whereas caecal ridinilazole concentrations
were well above the MIC [71], thus demonstrating the non-
absorbable nature of ridinilazole and minimal systemic exposure.
2.2.2. Phase 1 safety, tolerability and pharmacokinetics
of ridinilazole
The safety, tolerability and pharmacokinetics of ridinilazole were
examined in a phase 1, double-blind, placebo-controlled trial in
healthy volunteers [72]. Fifty-six male subjects received either a
once-daily oral dose of ridinilazole (2, 20, 100, 400, 1000 or 2000mg)
or a twice-daily oral dose of ridinilazole (200 mg or 500 mg) for 9
days with a ﬁnal dose on Day 10. Ridinilazole was found to be safe
and was well tolerated at all doses tested. The incidence of adverse
events (AEs) was comparable between subjects receiving ridinilazole
or placebo; AEs that were possibly or likely due to ridinilazole were
mild and there was no dose-dependent relationship between
ridinilazole and the incidence or severity of AEs. No clinically sig-
niﬁcant ﬁndingswere observed for blood pressure, body temperature,
12-lead electrocardiogram (ECG), clinical laboratory evaluations,
faecal occult blood or physical examination [72].
Oral administration of ridinilazole was associated with negligi-
ble systemic exposure. Although plasma ridinilazole concentrations
increased following drug administration with food, the maximum
observed plasma concentration was 0.305 ng/mL. Low systemic ex-
posurewas associatedwith high gastrointestinal levels of ridinilazole.
Following twice-daily dosing at 200mg, the mean (range) Day 5 and
Day 10 faecal concentrations of ridinilazole were 1466 (847–
2390) μg/g and 1364 (783–1980) μg/g, respectively [72]. These values
were markedly higher than the ridinilazole MIC range for C. diﬃcile
of 0.06–0.5 μg/mL (Table 1).
The phase 1 study also examined the effect of ridinilazole on gut
microbiota (Fig. 2). Culture methods were used to quantify changes
in the composition of gut microbiota, including the presence of Bac-
teroides, biﬁdobacteria, lactobacilli, total clostridia, total anaerobes,
lactose-fermenting Enterobacteriaceae and total aerobes. Faecal
samples were collected pre-dosing and at the mid and endpoint of
the 200 mg and 500 mg twice-daily dosing regimens. Repeat oral
administration of ridinilazole caused minimal changes in bacteri-
al counts, except for total clostridia in which a >3 log10 reduction
was observed at both doses at the midpoint of dosing; clostridial
counts remained below the limit of detection at the end of dosing
Fig. 1. Survival (%) of hamsters following infection with Clostridium diﬃcile BI1
(ribotype 027). VAN, vancomycin; FDX, ﬁdaxomicin; SMT, ridinilazole. Reproduced
from Ref. [70] (ﬁg. 1). By permission of Oxford University Press on behalf of The British
Society for Antimicrobial Chemotherapy.
Fig. 2. Change in gut microbiota composition for healthy volunteers in study Group
G, which included eight males who received a twice-daily 200mg oral dose of either
ridinilazole (n = 6) or placebo (n = 2). Microbiota composition, as measured by culture
techniques, is represented as mean log10 CFU/mL for the indicated bacteria. LFE,
lactose-fermenting Enterobacteriaceae. Reproduced from Ref. [72] (ﬁg. 2). By per-
mission of the original publisher BioMed Central.
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[72]. Overall, ridinilazole was associated with negligible changes in
counts of other bacterial groups, including Bacteroides, biﬁdobacteria
and lactobacilli, which have been associated with being impor-
tant components of the complex ecology of the healthy bowel
microbiota that protects against CDI (termed colonisation resis-
tance) [73,74]. These data indicate that ridinilazole causes minimal
damage to the gut microbiota, thus allowing the natural restora-
tion of colonisation resistance during CDI treatment. This lack of
collateral damage to the gut microbiota may result in reduced rates
of recurrent disease.
3. Discussion
In addition to the high burden that CDI poses to patients (re-
curring episodes of infection and increasedmorbidity andmortality),
there is also a growing economic burden to hospitals and the health-
care system, particularly in the costs of treating multiple episodes
of CDI [75]. Recent studies have estimated yearly costs of CDI at ca.
€3 billion in the EU and between US$436 million and US$3.2 billion
in the USA [76]. Thus, there exists a signiﬁcant unmet and increas-
ing medical need for new therapies to treat CDI, speciﬁcally those
that can reduce the rate of disease recurrence.
Understanding the role that the intestinal microbiome plays in
the pathogenesis of CDI is essential to the development of effec-
tive therapies for this burdensome, and in some instances fatal,
disease. It is known that mere exposure to C. diﬃcile spores through
the faeco–oral route does not necessarily lead to CDI, as favourable
conditions in the host gastrointestinal environment are required for
spore germination [77–79]. In addition, a critical function of the
normal gut microbiota is to maintain colonisation resistance, by
which pathogenic organisms are unable to establish and prolifer-
ate in the host gut [49,80].
The intestinalmicrobiotamediates colonisation resistance through
several direct and indirect mechanisms, such as nutrient metabo-
lism, niche exclusion, production of antimicrobial peptides and
modulation of the host immune system [49,81–84]. Hence, the
microbiota represents a fundamental component of host intesti-
nal physiology, playing central roles in metabolism and immune
function.
Antibiotic use in humans has been shown to disrupt the com-
position and to decrease the diversity of the gut microbiota [85].
This antibiotic-inducedmicrobial imbalance (or dysbiosis) is thought
to lead to functional changes in the host intestinal environment that
impair colonisation resistance, thereby conferring susceptibility to
CDI [80,86]. The risk of developing CDI is signiﬁcantly higher im-
mediately following or during antibiotic administration; the CDI
incidence rate was over two-fold higher with concomitant antibi-
otic therapy or when patients had received antibiotics in the previous
5 days [87]. In patients with recurrent CDI, there is decreased di-
versity in the intestinal microbiota compared with either non-CDI
patients or cured CDI patients who did not experience a recur-
rence [88].
Although colonisation resistance has been associated with spe-
ciﬁc bacterial taxonomic groups, such as Clostridium clusters IV and
XIVa [89], Clostridiales Incertae Sedis XI [90], butyrogenic bacte-
ria [82], B. fragilis [73] and Biﬁdobacterium longum [74], it has recently
been shown that different absolute compositions of bacterial com-
munities can protect against CDI and that a deﬁning characteristic
of a protective bacterial community is an appropriate level of di-
versity with a normal functional environment [86,91].
Ideal therapies for CDI would speciﬁcally target C. diﬃcile whilst
leaving the indigenous gut microbiota intact, thereby allowing res-
toration of colonisation resistance and the healthy microbiome
during treatment. Metronidazole and vancomycin currently remain
the mainstay antibiotics for treatment of CDI, but these agents have
a broad spectrum of activity and cause signiﬁcant disruption to the
normal gut microbiota [92]. The repeated use of these antibiotics
for treatment of recurrent CDI promotes dysbiosis, which further
impairs colonisation resistance. In addition, metronidazole and van-
comycin have been shown to promote the outgrowth of vancomycin-
resistant enterococci [93]. Owing to its narrow spectrum of activity,
minimal disruption to the normal intestinal microbiota and reduced
rates of recurrent disease, ﬁdaxomicin offers advantages over both
metronidazole and vancomycin for the treatment of CDI [73,89,94].
Thus far, FMT has been a highly successful therapy for multiple re-
current CDI, presumably due to restoration of a diverse faecal
microbiome with intact colonisation resistance [50]. FMT is typi-
cally used as a salvage therapy in the most severe cases of CDI, as
its eﬃcacy has not been fully validated for the treatment of initial
episodes of CDI. Furthermore, its eﬃcacy and long-term safety proﬁle
for treating multiple recurrent CDI requires further assessment in
RCTs.
Ridinilazole is a novel antibiotic that could potentially fulﬁl the
requirements for improved CDI treatment with its highly targeted
spectrum of activity and ability to spare the normal gut microbiota
[60,64,72]. Ridinilazole is bactericidal against C. diﬃcile and exhib-
its a prolonged PAE [58] that results in decreased cytotoxin titres
and spore counts [59,70]. Hamster models of clindamycin-induced
CDI have demonstrated the eﬃcacy of ridinilazole for treating acute
CDI and preventing recurrent disease [70,71]. In a phase 1 study,
oral ridinilazole was well tolerated, displayed low systemic expo-
sure and speciﬁcally targeted clostridia whilst sparing other anaerobic
and aerobic faecal bacteria [72]. Because ridinilazole therapy shows
negligible disruption to the normal gut microbiota, this agent has
the potential to treat CDI whilst signiﬁcantly reducing the likeli-
hood of disease recurrence.
Further studies in CDI patients are required to validate the ef-
ﬁcacy of ridinilazole for CDI treatment, although initial results from
the multicentre phase 2 CoDIFy trial of 100 CDI patients have dem-
onstrated superiority of ridinilazole over vancomycin on sustained
clinical response (66.7% vs. 42.4%, respectively) [95]. Sustained clin-
ical response was deﬁned as clinical cure at the end of the 10-day
treatment period and the absence of recurrence within 30 days of
treatment end. These early phase 2 results suggest that ridinilazole
may be effective at reducing disease recurrence, a central unmet need
in CDI treatment. Phase 3 studies will hopefully shed more light on
the clinical utility of ridinilazole in CDI.
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